Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

For Acadia’s Pimavanserin, The Second Time Is The Charm

This article was originally published in The Pink Sheet Daily

Executive Summary

Acadia’s serotonin 5-HT2A receptor blocker demonstrated efficacy in a Phase III trial in patients with Parkinson’s disease psychosis, giving the drug a second chance to reach the market. Pimavanserin previously failed to demonstrate efficacy in an original Phase III trial.

Advertisement

Related Content

Acadia’s Persistence With Pimavanserin In Parkinson’s Psychosis Pays Off
Acadia’s Persistence With Pimavanserin In Parkinson’s Psychosis Pays Off
Acadia Now Has The Cash To Finish Phase III On Its Own
Deals Of The Week: Sanofi, Teva, Ablexis; Kadmon Emerges From Stealth Mode

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS073548

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel